eXmoor Pharma and Royal Free London NHS Foundation Trust have announced a strategic collaboration to create a seamless […]

Foundation’s test to be used in Oxford-led blood biomarker trial

First long-acting therapy with three-monthly dosing to target root cause of cardiac disease

First PD-1 inhibitor plus ADC regimens for cisplatin-ineligible patients

Five-year deal aims to support UK biomedical talent and drive collaboration across sectors

Positive topline results highlight potential new option for secondary stroke prevention

Alvotech and Advanz Pharma secure EC authorisation for treatment of immune-mediated diseases

New patent strengthens IP position for treatment of influenza side effects

Protara’s phase 2 STARBORN-1 study reports high response rates and no serious adverse events

New authorisation marks major milestone in earlier treatment of skin cancer